"Likes" put Zarbee's in FDA crosshairs

Share this article:
"Likes" put Zarbee's in FDA cross-hairs
"Likes" put Zarbee's in FDA cross-hairs

“Liking” Facebook comments has landed OTC remedy maker Zarbee's on the FDA's dislike list. The regulator sent a Warning Letter to the manufacturer of products including Zarbee's Naturals Children's Cough Syrup + Mucus Relief, Zarbee's Naturals Children's Cough Syrup Nighttime and Zarbee's Naturals Children's Sleep over a host of online behaviors that the Food and Drug Administration says cross a line which puts the company's products firmly on its turf: drugs.

While kid-friendly bee packaging and ingredient lists comprised of items such as grapefruit seed extract and honey would appear to put the treatments in the “supplements” category, the FDA's letter shows that a recipe is not enough to keep a product off its watch list if product claims—and in this case endorsement of third-party claims— make it appear as though the maker is OK with language that indicates the treatment is a drug, which means it can cure, ameliorate or prevent a condition.

The list of transgressions includes liking comments such as “I've been battling either bronchitis or pneumonia for the last 18 days and have tried everything... [m]y throat and chest are beginning to feel better” and “I have a daughter born with cerebral palsy and she suffers from Complex Regional Pain Syndrome... [s]he took the samples you sent and slept through the night” because the agency considers the thumbs-up tantamount to “recommending or describing” the products as a cure or treatment that eases a condition.

Twitter postings “Try @Zarbees #naturalremedies for Cold and Cough Season” and “RT@MomCentral Have you tried #ZarbeesCough for cold and cough relief” also put the company on the FDA's naughty list because they “provide further evidence that your products are intended to be used as drugs.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...